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Abstract Introduction: Stenosis, mediated by neointimal hyperplasia and thrombosis, is a major limiting
factor in successful stent implantation. The introduction of a stent, coated in its endoluminal surface by
antihuman CD34 antibodies with endothelial progenitor cell-capturing properties, opens the possibility of
promoting a rapid and normal functioning coverage by endothelium and thus avoids both an excessive cell
proliferation within stent and the need for long-term dual antiplatelet therapy. These stents, developed for
adult coronary artery disease, have not yet been implanted in children or in those with congenital heart
disease. Objective and methods: In this paper, we describe the implantation of Genouss stents in three children
with cyanotic congenital heart disease and obstructed systemic-to-pulmonary shunts. We describe the use of
this stent and address its potential feasibility in paediatric congenital heart disease. Results: To maintain the
patency of two modified Blalock–Taussig shunts and one ductus arteriosus, four Genouss stents were
implanted in three infants with cyanotic heart disease. All procedures were immediately successful, with
resolution of stenosis and improvement in transcutaneous oxygen saturation from 66%6 3.6% to
92%6 2.6%. In the follow-up, one stent had no occlusion; however, the remaining two had partial
occlusion after 5 and 5.5 months, which were successfully managed with balloon dilatation preceding elective
definitive surgical correction. Conclusion: In our preliminary experience, we demonstrated that Genouss stent
implantation was feasible in infants with complex congenital heart disease. Additional studies with larger samples
and longer follow-up are required to confirm the potential benefits of this technology in this clinical setting.
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I
N THE CURRENT ERA OF EARLY SURGICAL CORRECTION,
palliation with surgical systemic-to-pulmonary
artery shunts remains a valid strategy in selected
cases of duct-dependent congenital heart disease.
However, obstruction of these shunts is reported to
range between 6.7% and 11.8%.1–3
Another proposed early palliative strategy for
transient pulmonary blood flow maintenance is
ductus arteriosus stenting.4–6 In this case, despite
improving results the success is hampered by early
occlusion.7–9
This problem has been dealt with platelet anti-
aggregation, acute thrombolysis, percutaneous balloon
angioplasty, or re-stenting.10–13 The latter offers
excellent immediate results but stent patency is usually
unsatisfactory,9,14,15 with rates of re-intervention that
can reach 45% after 1 year of follow-up.15
This concerning occlusion rate is multifactorial
and results from thrombotic events or neointimal
hyperplasia. In adult coronary artery disease, a new
strategy that is being tested to circumvent stent
occlusion consists of utilising antihuman CD34
antibodies on the stent’s endoluminal surface, to
fix progenitor endothelial progenitor cells and
quickly promote endothelialisation (Genouss R-stent;
OrbusNeich Medical Technologies, Fourt Lauderdale,
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Florida, United States of America). Its use in the
context of coronary revascularisation has been tested
in various adult patient groups and clinical settings,
with satisfactory initial results16–19 but not in
children or in those with congenital heart disease.
In this article, we report the use of Genouss stent
in systemic-to-pulmonary shunts or patent ductus
arteriosus in neonates and infants with congenital
heart disease. This approach, which may take
advantage of the higher level of circulating endothe-
lial progenitor cells in younger patients, has not been
previously described in this clinical setting.
Cases 1 and 2
We describe the cases of two newborns with severe
tetralogy of Fallot and hypoplastic pulmonary arteries
who underwent placement of 4mm Goretexs
modified Blalock–Taussig shunts, each. Both devel-
oped stenosis of the modified Blalock–Taussig shunts
with cyanosis, 1 day and 3 months after surgery,
respectively. A significant obstruction was found in
the shunt’s mid-segment. After balloon pre-dilatation,
stent angioplasty was performed with Genouss stents
(one patient with 43 15mm and 43 13mm; other
with 4318mm stent) with satisfactory immediate
angiographic and clinical result – peripheral oxygen
saturation significantly improved from 64% to 91%.
Immediately after the procedures, the patients
were maintained under heparin perfusion for
24 hours and were started on a double antiplatelet
regimen with acetylsalicylic acid (5mg/kg/day) and
clopidogrel (1mg/kg/day).
Elective re-catheterisation, after 5 months under
dual antiplatelet therapy, exhibited partial stent
occlusion in one patient. The other was re-catheterised
at 10 months post-implantation, also electively, and
again under the same antiplatelet regimen, and
showed an adequately functioning stent.
Elective surgical correction ensued in both,
successfully (Figs 1–3).
Case 3
A newborn girl with a prenatal diagnosis of
pulmonary atresia and intact interventricular septum
with borderline hypoplastic right ventricle – bipartite
right ventricle, tricuspid valve z-score 20.4 –
underwent percutaneous radiofrequency pulmonary
valve perforation.
Figure 1.
Case 2 – Blalock–Taussig shunt occlusion. Antero-posterior
incidence.
Figure 2.
Case 2 – Genous stent being deployed on Blalock–Taussig shunt.
Antero-posterior incidence.
Figure 3.
Case 2 – Blalock–Taussig shunt after stent expansion. Antero-
posterior incidence.
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At 1.5 months old, despite good outflow
obstruction, the right ventricle was still unsuitable
for maintenance of pulmonary blood flow and the
patient was dependent on a progressively restrictive
patent ductus arteriosus. A narrowed patent ductus
arteriosus was stented with a Genouss stent
(43 9mm). She was discharged on a dual antiplate-
let regimen with acetylsalicylic acid (5mg/kg/day)
and clopidogrel (1mg/kg/day). At 7 months of age,
she was re-admitted for severe desaturation. The
catheterisation showed severe residual pulmonary
valve stenosis and partial in-stent occlusion, despite
dual antiplatelet therapy. Both were treated with
balloon dilation, and she was discharged with an
improved saturation of 95%.
At 14 months, a third and final pulmonary
valvuloplasty was performed, and the stented ductus
was found to be adequately patent. Currently, she is
2 years old, and has an adequately functioning right
ventricle and is planned for a percutaneous closure
of the patent ductus arteriosus, medicated with
acetylsalicylic acid.
Discussion
Stent deployment generates vascular trauma with
dilatation and intimal stretch or tear, which ideally
ends in its endothelialisation by mature and
functional endothelial cells. However, vascular wall
injury generates an inflammatory reaction involving
macrophages, platelets, and fibrin accumulation
along with neovascularisation, which may explain
the occurrence of mural thrombi.20–22
The immediate outcome after stent deployment
depends on stenosis resolution. However, a favour-
able mid- to long-term result is dependent on the
degree of cell proliferation that occurs in its lumen,
which can obstruct blood flow, particularly in
smaller vessels, such as is the case of modified
Blalock–Taussig shunts and patent ductus arteriosus.
This problem is both common and important after
coronary stenting, and thus strategies have been
developed to address this issue.
After the advent of cytostatic or cytotoxic drug-
coated stents, the phenomenon of excessive neointimal
proliferation was reduced; however, it also resulted in
a delay of endothelialisation by inhibiting the
proliferation of several undifferentiated cell clusters
involved in the native physiological reaction to stent
implantation. Blood exposure to subendothelial
prothrombotic constituents, to tissue factor and to
the stent itself, predisposes to thrombosis. This
justifies the need for long-term dual antiplatelet
therapy until complete endothelialisation is com-
pleted, which carries increased morbidity in specific
clinical settings.
In short, there are physiological processes that are
intended to be prevented, namely, stenosis caused
by physiological, but harmful, excessive cell pro-
liferation inside the stent; thrombosis due to late
stent endothelialisation promoted by eluted drugs
used for stenosis prevention; and bleeding caused by
dual antiplatelet therapy used in order to prevent
thrombosis.
Identification of endothelial progenitor cells and
control of their differentiation in the right site at
the right time is a goal long ago pursued by
scientific community in general, and that which
studies ischaemic disease in particular. However, the
inability to identify with high accuracy these cells
has been the limiting factor for achieving this goal23
and to control angiogenesis, with all its consequent
benefits in the field of ischaemic disease.
Genouss stent is composed of a grid of 316
stainless steel, coated in endoluminal surface by a
polysaccharide layer containing murine monoclonal
antihuman CD341 antibodies, which attracts
endothelial progenitor cells.24 Animal studies
showed its complete endothelialisation within few
days.21,22 Moreover, it is thought that the generation
of an intact endothelial layer with normal homeo-
static properties leads to inhibition of neointimal
proliferation by production of anti-inflammatory and
anti-proliferative factors.25–27 HEALING-FIM trial,
the first study in humans, showed its safety, with
only one out of 16 patients having a target vessel
revascularisation procedure within 9 months, being
only 1 month under dual antiplatelet therapy.17
In HEALING II trial,18 a prospective multi-
centre registry, with 63 patients with significant
coronary lesions, Genouss stent had a satisfactory
performance, despite the fact that the patients were
treated with two antiplatelet agents for only the
first month after implantation. These results were
supported by those of e-HEALING registry.19
There are few data concerning the advantages of
Genouss stent in thrombosis and stenosis preven-
tion in the medium to long term, in comparison
with drug eluting stents and bare metal stents.24
Currently, there is an ongoing multi-centre rando-
mised study – TRI-stent Adjudication Study –
comparing antihuman CD34 antibody-coated
stents, drug-eluting stents, and bare metal stents
and quantifying circulating endothelial progenitor
cells at the time of stent deployment.
On the basis of existing data of a short series of
patients, the rate of modified Blalock–Taussig shunt
occlusion was described to range from 9% to 12%.2,3
The physiopathology of thrombosis and endothelial
hyperplasia is potentiated by surgical iatrogenesis
such as shunt kinking or proximal subclavian artery
stenosis, and frequently accompanying coagulation
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disturbances among congenital heart disease patients,
particularly those with cyanotic disorders. Shunt
occlusion requires immediate treatment. If medical
thrombolysis is unsuccessful, stenting of these
modified Blalock–Taussig shunts is the best option.
Results showed that stent implantation is an
effective treatment to improve oxygen saturation
in an acute setting, having high rates of immediate
success.10,28–30 However, medium- to long-term
results are not so satisfactory, and there are reports
in which almost one-third of the patients did not
reach second stage palliation surgery.10
Arterial duct stenting has been suggested as an
alternative to surgery in duct-dependent pulmonary
circulation, particularly in high-risk neonates.7,31
However, despite technical advances, the durability
of this approach was shorter than that of surgical
shunts. Acute procedural failure is around 10%, and
occlusion still occurs invariably within few
months.5,31 Several technical aspects are important,
and results are less satisfactory when the duct has a
tortuous morphology or the duct tissue is not
completely covered by stents.14,29
Favourable outcomes recently demonstrated by
Genouss stent in adult population of coronary
patients, conceptually, open the field for its evalua-
tion in other settings, for example in children. In
addition, it is hypothesised that there is a higher
proportion of circulating endothelial progenitor cells
in young children, which could potentially make the
mechanism of stent endothelialisation particularly
efficient in this setting.
Our initial experience in a paediatric population
with cyanotic heart disease showed acute success in
all patients.
In the complex clinical settings reported in these
three cases, in terms of traditional short and middle
term stent’s rate of occlusion, as mentioned earlier
in this text, in this serie two out of four stents
remained free of haemodynamic significant stenosis
until definite correction of the cardiopathy was
achieved; one stent implanted in a modified
Blalock–Taussig shunt showed partial stenosis,
clinically silent, in an elective procedure performed
5 months after implantation; and the remaining
stent implanted in a slim patent ductus arteriosus
exhibited partial stenosis, 5.5 months later, treated
with percutaneous balloon dilatation (Table 1).
This is an initial report using an antihuman
CD34 antibody-coated stent in the paediatric
population, and these results should be looked at
carefully because of the limited number of cases.
Conclusion
The benefits, in terms of prognosis and safety, of
using an antihuman CD34 antibody-coated stent are
now being addressed in adult patients with coronary
artery disease, and initial studies had satisfactory
results. We describe three cases of Genouss stent
implantation in children in which the maintenance of
patency of the angioplastied vessels was essential for
survival, demonstrating that its use is feasible.
The potential advantages of this kind of stent
over conventional stents are not yet addressed in
children, and this issue obviously requires trials
with larger populations comparing it directly with
other types of currently commercialised stents.
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